Advertisement

Vaccination in Organ Transplant Patients

  • Lara Danziger-IsakovEmail author
  • Camille Nelson Kotton
Chapter

Abstract

Vaccines are an essential component of protection against infection after solid organ transplantation for both children and adults. Unfortunately, many transplant recipients are undervaccinated. In general, vaccination before transplantation results in better immunologic response, and the period before transplant is a special opportunity to provide protection for this vulnerable population. Live vaccines, such as MMR, varicella/zoster, nasal influenza, yellow fever, oral polio, and others are generally contraindicated after transplant. While the immunologic response induced by vaccination may be less robust in this population, due to exogenous immunosuppression, organ disease, and other comorbidities, this protection may be sufficient to protect or attenuate disease. Various individual vaccines are discussed in detail in this review.

Keywords

Vaccine Immunization Transplant Immunity Protection Prevention 

References

  1. 1.
    Williams WW, Lu PJ, O’Halloran A, Kim DK, Grohskopf LA, Pilishvili T, et al. Surveillance of vaccination coverage among adult populations – United States, 2015. Morb Mortal Wkly Rep Surveill Summ. 2017;66(11):1–28.Google Scholar
  2. 2.
    Diana A, Posfay-Barbe KM, Belli DC, Siegrist CA. Vaccine-induced immunity in children after orthotopic liver transplantation: a 12-yr review of the Swiss national reference center. Pediatr Transplant. 2007;11(1):31–7.PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Chaves TS, Pereira LM, De Santos SS, David-Neto E, Lopes MH. Evaluation of the vaccination status in pediatric renal transplant recipients. Pediatr Transplant. 2008;12(4):432–5.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Dehghani SM, Shakiba MA, Ziaeyan M, Imanieh MH, Haghighat M, Bahador A, et al. Vaccination status in pediatric liver transplant candidates. Pediatr Transplant. 2009;13(7):820–2.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Chesi C, Gunther M, Huzly D, Neuhaus R, Reinke P, Engelmann HB, et al. Immunization of liver and renal transplant recipients: a seroepidemiological and sociodemographic survey. Transpl Infect Dis. 2009;11(6):507–12.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    CDC Website Immunization Schedules available from https://www.cdc.gov/vaccines/schedules/
  7. 7.
    Katerinis I, Hadaya K, Duquesnoy R, Ferrari-Lacraz S, Meier S, van Delden C, et al. De novo anti-HLA antibody after pandemic H1N1 and seasonal influenza immunization in kidney transplant recipients. Am J Transplant. 2011;11(8):1727–33.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Danziger-Isakov L, Cherkassky L, Siegel H, McManamon M, Kramer K, Budev M, et al. Effects of influenza immunization on humoral and cellular alloreactivity in humans. Transplantation. 2010;89(7):838–44.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Agarwal N, Ollington K, Kaneshiro M, Frenck R, Melmed GY. Are immunosuppressive medications associated with decreased responses to routine immunizations? A systematic review. Vaccine. 2012;30(8):1413–24.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Kumar D, Blumberg EA, Danziger-Isakov L, Kotton CN, Halasa NB, Ison MG, et al. Influenza vaccination in the organ transplant recipient: review and summary recommendations. Am J Transplant. 2011;11(10):2020–30.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Danziger-Isakov L, Kumar D, Practice ASTIDCo. Vaccination in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):311–7.CrossRefGoogle Scholar
  12. 12.
    Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med. 2007;357(25):2601–14.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):309–18.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57(RR-5):1–30; quiz CE2-4PubMedPubMedCentralGoogle Scholar
  15. 15.
    Centers for Disease Control Health Information for International Travel. Atlanta, GA2012 [cited 2012 April 14]. Available from: https://wwwnc.cdc.gov/travel
  16. 16.
    Kumar D, Michaels MG, Morris MI, Green M, Avery RK, Liu C, et al. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect Dis. 2010;10(8):521–6.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Yen C, Jakob K, Esona MD, Peckham X, Rausch J, Hull JJ, et al. Detection of fecal shedding of rotavirus vaccine in infants following their first dose of pentavalent rotavirus vaccine. Vaccine. 2011;29(24):4151–5.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Gisel JJ, Brumble LM, Johnson MM. Bordetella bronchiseptica pneumonia in a kidney-pancreas transplant patient after exposure to recently vaccinated dogs. Transpl Infect Dis. 2010;12(1):73–6.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Kotton CN. Zoonoses in solid-organ and hematopoietic stem cell transplant recipients. Clin Infect Dis. 2007;44(6):857–66.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    CDC. Recommended immunization schedule for persons aged 0 through 6 years 2012 [cited 2012 June 15]. Available from: https://www.cdc.gov/vaccines/schedules/easy-to-read/child.html
  21. 21.
    Gottlieb J, Schulz TF, Welte T, Fuehner T, Dierich M, Simon AR, et al. Community-acquired respiratory viral infections in lung transplant recipients: a single season cohort study. Transplantation. 2009;87(10):1530–7.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Hopkins P, McNeil K, Kermeen F, Musk M, McQueen E, Mackay I, et al. Human metapneumovirus in lung transplant recipients and comparison to respiratory syncytial virus. Am J Respir Crit Care Med. 2008;178(8):876–81.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Ison MG, Sharma A, Shepard JA, Wain JC, Ginns LC. Outcome of influenza infection managed with oseltamivir in lung transplant recipients. J Heart Lung Transplant. 2008;27(3):282–8.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Vilchez RA, McCurry K, Dauber J, Lacono A, Griffith B, Fung J, et al. Influenza virus infection in adult solid organ transplant recipients. Am J Transplant. 2002;2(3):287–91.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Kim DK, Riley LE, Harriman KH, Hunter P, Bridges CB. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older - United States, 2017. MMWR Morb Mortal Wkly Rep. 2017;66(5):136–8.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Robinson CL, Romero JR, Kempe A, Pellegrini C. Advisory Committee on Immunization Practices Child/Adolescent Immunization Work G. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger – United States, 2017. MMWR Morb Mortal Wkly Rep. 2017;66(5):134–5.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Recommended Adult Immunization Schedule for United States 2012 available at www.cdc.gov/vaccines/recs/schedules/downloads/adult/mmwr-adult-schedule.pdf. Morbidity and Mortality Weekly Report (MMWR). 2012;61(04). The 2018 version is on the website at https://www.cdc.gov/vaccines/schedules/ or https://www.cdc.gov/vaccines/schedules/downloads/adult/adult-schedule-easy-read-bw.pdf
  28. 28.
    Kotton CN. Optimizing the immunogenicity of pandemic H1N1 2009 influenza vaccine in adult organ transplant patients. Expert Rev Vaccines. 2012;11(4):423–6.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Blumberg EA, Albano C, Pruett T, Isaacs R, Fitzpatrick J, Bergin J, et al. The immunogenicity of influenza virus vaccine in solid organ transplant recipients. Clin Infect Dis. 1996;22(2):295–302.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Lawal A, Basler C, Branch A, Gutierrez J, Schwartz M, Schiano TD. Influenza vaccination in orthotopic liver transplant recipients: absence of post administration ALT elevation. Am J Transplant. 2004;4(11):1805–9.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Birdwell KA, Ikizler MR, Sannella EC, Wang L, Byrne DW, Ikizler TA, et al. Decreased antibody response to influenza vaccination in kidney transplant recipients: a prospective cohort study. Am J Kidney Dis. 2009;54(1):112–21.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Chon WJ, Kadambi PV, Harland RC, Thistlethwaite JR, West BL, Udani S, et al. Changing attitudes toward influenza vaccination in U.S. Kidney transplant programs over the past decade. Clin J Am Soc Nephrol. 2010;5(9):1637–41.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Kumar D, Morris MI, Kotton CN, Fischer SA, Michaels MG, Allen U, et al. Guidance on novel influenza A/H1N1 in solid organ transplant recipients. Am J Transplant. 2010 Jan;10(1):18–25.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Benden C, Danziger-Isakov LA, Astor T, Aurora P, Bluemchen K, Boyer D, et al. Variability in immunization guidelines in children before and after lung transplantation. Pediatr Transplant. 2007;11(8):882–7.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Altamirano-Diaz L, West L, Humar A, Ely L, Urschel S, Gubbay J, et al. Early post-transplant vaccination with pandemic influenza A/H1N1 vaccine in pediatric heart transplant recipients. Pediatr Transplant. 2011;15(2):172–5.PubMedPubMedCentralGoogle Scholar
  36. 36.
    Madan RP, Tan M, Fernandez-Sesma A, Moran TM, Emre S, Campbell A, et al. A prospective, comparative study of the immune response to inactivated influenza vaccine in pediatric liver transplant recipients and their healthy siblings. Clin Infect Dis. 2008;46(5):712–8.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Hojsak I, Avitzur Y, Mor E, Shamir R, Haimi-Cohen Y, Zakay-Rones Z, et al. Antibody response to influenza vaccine in pediatric liver transplant recipients. Pediatr Infect Dis J. 2011;30(6):491–4.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Nailescu C, Xu X, Zhou H, Hall H, Wilson AC, Leiser JD, et al. Influenza vaccine after pediatric kidney transplant: a Midwest Pediatric Nephrology Consortium study. Pediatr Nephrol. 2011;26(3):459–67.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Mack DR, Chartrand SA, Ruby EI, Antonson DL, Shaw BW Jr, Heffron TG. Influenza vaccination following liver transplantation in children. Liver Transpl Surg. 1996;2(6):431–7.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Goldschmidt I, Pfister ED, Becker M, Hackl S, Bott OJ, Baumann U, et al. Acceptance and adverse events of the 2009 H1N1 vaccination in immunosuppressed pediatric liver transplant recipients. J Pediatr. 2011;158(2):329–33.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Esposito S, Meregalli E, Daleno C, Ghio L, Tagliabue C, Valzano A, et al. An open-label, randomized clinical trial assessing immunogenicity, safety and tolerability of pandemic influenza A/H1N1 MF59-adjuvanted vaccine administered sequentially or simultaneously with seasonal virosomal-adjuvanted influenza vaccine to paediatric kidney transplant recipients. Nephrol Dial Transplant. 2011 Jun;26(6):2018–24.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Long CB, Ramos I, Rastogi D, Manwani D, Janow G, Del Rio M, et al. Humoral and cell-mediated immune responses to monovalent 2009 influenza A/H1N1 and seasonal trivalent influenza vaccines in high-risk children. J Pediatr. 2012;160(1):74–81.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Haller W, Buttery J, Laurie K, Beyerle K, Hardikar W, Alex G. Immune response to pandemic H1N1 2009 influenza a vaccination in pediatric liver transplant recipients. Liver Transpl. 2011;17(8):914–20.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    GiaQuinta S, Michaels MG, McCullers JA, Wang L, Fonnesbeck C, O'Shea A, et al. Randomized, double-blind comparison of standard-dose vs. high-dose trivalent inactivated influenza vaccine in pediatric solid organ transplant patients. Pediatr Transplant. 2015;19(2):219–28.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Blumberg EA, Brozena SC, Stutman P, Wood D, Phan HM, Musher DM. Immunogenicity of pneumococcal vaccine in heart transplant recipients. Clin Infect Dis. 2001;32(2):307–10.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Lindemann M, Witzke O, Lutkes P, Fiedler M, Kreuzfelder E, Philipp T, et al. ELISpot assay as a sensitive tool to detect cellular immunity following influenza vaccination in kidney transplant recipients. Clin Immunol. 2006;120(3):342–8.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Willcocks LC, Chaudhry AN, Smith JC, Ojha S, Doffinger R, Watson CJ, et al. The effect of sirolimus therapy on vaccine responses in transplant recipients. Am J Transplant. 2007;7(8):2006–11.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Kumar D, Rotstein C, Miyata G, Arlen D, Humar A. Randomized, double-blind, controlled trial of pneumococcal vaccination in renal transplant recipients. J Infect Dis. 2003;187(10):1639–45.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Kumar D, Chen MH, Wong G, Cobos I, Welsh B, Siegal D, et al. A randomized, double-blind, placebo-controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in adult liver transplant recipients. Clin Infect Dis. 2008;47(7):885–92.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Barton M, Wasfy S, Melbourne T, Hebert D, Moore D, Robinson J, et al. Sustainability of humoral responses to varicella vaccine in pediatric transplant recipients following a pretransplantation immunization strategy. Pediatr Transplant. 2009;13(8):1007–13.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Gattringer R, Winkler H, Roedler S, Jaksch P, Herkner H, Burgmann H. Immunogenicity of a combined schedule of 7-valent pneumococcal conjugate vaccine followed by a 23-valent polysaccharide vaccine in adult recipients of heart or lung transplants. Transpl Infect Dis. 2011;13(5):540–4.PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Ljungman P, de la Camara R, Perez-Bercoff L, Abecasis M, Nieto Campuzano JB, Cannata-Ortiz MJ, et al. Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients. Haematologica. 2011;96(8):1231–5.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Romero-Steiner S, Musher DM, Cetron MS, Pais LB, Groover JE, Fiore AE, et al. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin Infect Dis. 1999;29:281–8.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Pourfarziani V, Ramezani MB, Taheri S, Izadi M, Einollahi B. Immunogenicity of pneumococcal vaccination in renal transplant recipients and hemodialysis patients: a comparative controlled trial. Ann Transplant. 2008;13(3):43–7.PubMedPubMedCentralGoogle Scholar
  55. 55.
    Avery RK, Michaels M. Update on immunizations in solid organ transplant recipients: what clinicians need to know. Am J Transplant. 2008;8(1):9–14.PubMedCrossRefPubMedCentralGoogle Scholar
  56. 56.
    Zlamy M, Elias J, Vogel U, Frosch M, Jeller V, Cortina G, et al. Immunogenicity of conjugate meningococcus C vaccine in pediatric solid organ transplant recipients. Vaccine. 2011;29(37):6163–6.PubMedCrossRefPubMedCentralGoogle Scholar
  57. 57.
    Cohen JI, Brunell PA, Straus SE, Krause PR. Recent advances in varicella-zoster virus infection. Ann Intern Med. 1999;130(11):922–32.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Gnann JW. Herpes simplex and varicella-zoster virus infection after hematopoietic stem cell or solid organ transplantation. In: Bowden R, Ljungman P, Snydman D, editors. Transplant infections. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2010. p. 391–410.Google Scholar
  59. 59.
    Heininger U, Seward JF. Varicella. Lancet. 2006;368(9544):1365–76.PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    Dworkin RH, Johnson RW, Breuer J, Gnann JW, Levin MJ, Backonja M, et al. Recommendations for the management of herpes zoster. Clin Infect Dis. 2007;44(Suppl 1):S1–26.PubMedCrossRefPubMedCentralGoogle Scholar
  61. 61.
    Gnann JW Jr, Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med. 2002;347(5):340–6.PubMedCrossRefPubMedCentralGoogle Scholar
  62. 62.
    Pandya A, Wasfy S, Hebert D, Allen UD. Varicella-zoster infection in pediatric solid-organ transplant recipients: a hospital-based study in the prevaricella vaccine era. Pediatr Transplant. 2001;5(3):153–9.PubMedCrossRefPubMedCentralGoogle Scholar
  63. 63.
    Weibel RE, Neff BJ, Kuter BJ, Guess HA, Rothenberger CA, Fitzgerald AJ, et al. Live attenuated varicella virus vaccine. Efficacy trial in healthy children. N Engl J Med. 1984;310(22):1409–15.PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Weibel RE, Kuter BJ, Neff BJ, Rothenberger CA, Fitzgerald AJ, Connor KA, et al. Live Oka/Merck varicella vaccine in healthy children. Further clinical and laboratory assessment. JAMA. 1985;254(17):2435–9.PubMedCrossRefPubMedCentralGoogle Scholar
  65. 65.
    Gershon AA, Steinberg SP, LaRussa P, Ferrara A, Hammerschlag M, Gelb L. Immunization of healthy adults with live attenuated varicella vaccine. J Infect Dis. 1988;158(1):132–7.PubMedCrossRefPubMedCentralGoogle Scholar
  66. 66.
    Shinefield H, Black S, Digilio L, Reisinger K, Blatter M, Gress JO, et al. Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children. Pediatr Infect Dis J. 2005;24(8):665–9.PubMedCrossRefPubMedCentralGoogle Scholar
  67. 67.
    Scheifele DW, Halperin SA, Diaz-Mitoma F. Three-year follow-up of protection rates in children given varicella vaccine. Can J Infect Dis. 2002;13(6):382–6.PubMedPubMedCentralCrossRefGoogle Scholar
  68. 68.
    Broyer M, Tete MJ, Guest G, Gagnadoux MF, Rouzioux C. Varicella and zoster in children after kidney transplantation: long-term results of vaccination. Pediatrics. 1997;99(1):35–9.PubMedCrossRefPubMedCentralGoogle Scholar
  69. 69.
    Warmington L, Lee BE, Robinson JL. Loss of antibodies to measles and varicella following solid organ transplantation in children. Pediatr Transplant. 2005;9(3):311–4.PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
    Shinjoh M, Miyairi I, Hoshino K, Takahashi T, Nakayama T. Effective and safe immunizations with live-attenuated vaccines for children after living donor liver transplantation. Vaccine. 2008;26(52):6859–63.PubMedCrossRefPubMedCentralGoogle Scholar
  71. 71.
    Khan S, Erlichman J, Rand EB. Live virus immunization after orthotopic liver transplantation. Pediatr Transplant. 2006;10(1):78–82.PubMedCrossRefPubMedCentralGoogle Scholar
  72. 72.
    Chaves Tdo S, Lopes MH, de Souza VA, Dos Santos SS, Pereira LM, Reis AD, et al. Seroprevalence of antibodies against varicella-zoster virus and response to the varicella vaccine in pediatric renal transplant patients. Pediatr Transplant. 2005;9(2):192–6.PubMedCrossRefPubMedCentralGoogle Scholar
  73. 73.
    Kano H, Mizuta K, Sakakihara Y, Kato H, Miki Y, Shibuya N, et al. Efficacy and safety of immunization for pre- and post- liver transplant children. Transplantation. 2002;74(4):543–50.PubMedPubMedCentralCrossRefGoogle Scholar
  74. 74.
    Weinberg A, Horslen SP, Kaufman SS, Jesser R, Devoll-Zabrocki A, Fleckten BL, et al. Safety and immunogenicity of varicella-zoster virus vaccine in pediatric liver and intestine transplant recipients. Am J Transplant. 2006;6(3):565–8.PubMedCrossRefPubMedCentralGoogle Scholar
  75. 75.
    Posfay-Barbe KM, Pittet LF, Sottas C, Grillet S, Wildhaber BE, Rodriguez M, et al. Varicella-zoster immunization in pediatric liver transplant recipients: safe and immunogenic. Am J Transplant. 2012;12(11):2974–85.PubMedCrossRefPubMedCentralGoogle Scholar
  76. 76.
    Miller GG, Dummer JS. Herpes simplex and varicella zoster viruses: forgotten but not gone. Am J Transplant. 2007;7(4):741–7.PubMedCrossRefPubMedCentralGoogle Scholar
  77. 77.
    Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087–96.PubMedCrossRefPubMedCentralGoogle Scholar
  78. 78.
    Lima EQ, Silva RG, Fernandes IM, Abbud-Filho M, Burdmann EA. Tetanus-induced acute kidney injury in a renal transplant recipient. Am J Trop Med Hyg. 2007;77(2):400–2.PubMedCrossRefPubMedCentralGoogle Scholar
  79. 79.
    Huzly D, Neifer S, Reinke P, Schroder K, Schonfeld C, Hofmann T, et al. Routine immunizations in adult renal transplant recipients. Transplantation. 1997;63(6):839–45.PubMedCrossRefPubMedCentralGoogle Scholar
  80. 80.
    Ner Z, Ross LA, Horn MV, Keens TG, MacLaughlin EF, Starnes VA, et al. Bordetella bronchiseptica infection in pediatric lung transplant recipients. Pediatr Transplant. 2003;7(5):413–7.PubMedCrossRefPubMedCentralGoogle Scholar
  81. 81.
    Chauncey JB, Schaberg DR. Interstitial pneumonia caused by Bordetella bronchiseptica in a heart transplant patient. Transplantation. 1990;49(4):817–9.PubMedCrossRefPubMedCentralGoogle Scholar
  82. 82.
    Choy KW, Wulffraat NM, Wolfs TF, Geelen SP, Kraaijeveld CA, Fleer A. Bordetella bronchiseptica respiratory infection in a child after bone marrow transplantation. Pediatr Infect Dis J. 1999;18(5):481–3.PubMedCrossRefPubMedCentralGoogle Scholar
  83. 83.
    Bauwens JE, Spach DH, Schacker TW, Mustafa MM, Bowden RA. Bordetella bronchiseptica pneumonia and bacteremia following bone marrow transplantation. J Clin Microbiol. 1992;30(9):2474–5.PubMedPubMedCentralGoogle Scholar
  84. 84.
    Berkelman RL. Human illness associated with use of veterinary vaccines. Clin Infect Dis. 2003;37(3):407–14.PubMedCrossRefPubMedCentralGoogle Scholar
  85. 85.
    Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S, Hernandez M, Quinones-Falconi F, Bautista E, et al. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med. 2009;361(7):680–9.PubMedCrossRefPubMedCentralGoogle Scholar
  86. 86.
    CDC. Hepatitis B Information for Health Professionals [cited 2012 January 30]. Available from: http://www.cdc.gov/hepatitis/HBV/index.htm
  87. 87.
    Australian Government Department of Health and Ageing: Immunise Australia Program [cited 2012 January 30]. Available from: http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/nips2.
  88. 88.
    Report on First survey of Immunisation Programs in Europe. 2007 April 2007. VENICE project.Google Scholar
  89. 89.
    Public Health Agency of Canada: Immunizations & Vaccines [cited 2012 January 30]. Available from: http://www.phac-aspc.gc.ca/im/index-eng.php.
  90. 90.
    Su WJ, Ho MC, Ni YH, Chen HL, Hu RH, Wu YM, et al. High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection. J Pediatr Gastroenterol Nutr. 2009;48(2):203–8.PubMedCrossRefPubMedCentralGoogle Scholar
  91. 91.
    Idilman R, Colantoni A, De Maria N, Ustun C, Sam R, Ing TS, et al. Impaired antibody response rates after high dose short interval hepatitis B virus vaccination of immunosuppressed individuals. Hepato-Gastroenterology. 2003;50(49):217–21.PubMedPubMedCentralGoogle Scholar
  92. 92.
    Angelico M, Di Paolo D, Trinito MO, Petrolati A, Araco A, Zazza S, et al. Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology. 2002;35(1):176–81.PubMedCrossRefPubMedCentralGoogle Scholar
  93. 93.
    Ishigami M, Kamei H, Nakamura T, Katano Y, Ando H, Kiuchi T, et al. Different effect of HBV vaccine after liver transplantation between chronic HBV carriers and non-HBV patients who received HBcAb-positive grafts. J Gastroenterol. 2011;46(3):367–77.PubMedCrossRefPubMedCentralGoogle Scholar
  94. 94.
    Klevens RM, Miller JT, Iqbal K, Thomas A, Rizzo EM, Hanson H, et al. The evolving epidemiology of hepatitis A in the United States: incidence and molecular epidemiology from population-based surveillance, 2005–2007. Arch Intern Med. 2010;170(20):1811–8.PubMedCrossRefPubMedCentralGoogle Scholar
  95. 95.
    CDC. Hepatitis A Information for Health Professionals [cited 2012 January 30]. Available from: https://www.cdc.gov/hepatitis/hav/
  96. 96.
    Park GC, Hwang S, Yu YD, Park PJ, Choi YI, Song GW, et al. Intractable recurrent hepatitis A virus infection requiring repeated liver transplantation: a case report. Transplant Proc. 2010;42(10):4658–60.PubMedCrossRefPubMedCentralGoogle Scholar
  97. 97.
    Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50(3):661–2.PubMedCrossRefPubMedCentralGoogle Scholar
  98. 98.
    Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335–74.PubMedCrossRefPubMedCentralGoogle Scholar
  99. 99.
    Arslan M, Wiesner RH, Sievers C, Egan K, Zein NN. Double-dose accelerated hepatitis B vaccine in patients with end-stage liver disease. Liver Transpl. 2001;7(4):314–20.PubMedCrossRefPubMedCentralGoogle Scholar
  100. 100.
    Dumot JA, Barnes DS, Younossi Z, Gordon SM, Avery RK, Domen RE, et al. Immunogenicity of hepatitis A vaccine in decompensated liver disease. Am J Gastroenterol. 1999;94(6):1601–4.PubMedCrossRefPubMedCentralGoogle Scholar
  101. 101.
    Stark K, Gunther M, Neuhaus R, Reinke P, Schroder K, Linnig S, et al. Immunogenicity and safety of hepatitis A vaccine in liver and renal transplant recipients. J Infect Dis. 1999;180(6):2014–7.PubMedCrossRefPubMedCentralGoogle Scholar
  102. 102.
    Ferreira CT, da Silveira TR, Vieira SM, Taniguchi A, Pereira-Lima J. Immunogenicity and safety of hepatitis A vaccine in children with chronic liver disease. J Pediatr Gastroenterol Nutr. 2003;37(3):258–61.PubMedCrossRefPubMedCentralGoogle Scholar
  103. 103.
    Gunther M, Stark K, Neuhaus R, Reinke P, Schroder K, Bienzle U. Rapid decline of antibodies after hepatitis A immunization in liver and renal transplant recipients. Transplantation. 2001;71(3):477–9.PubMedCrossRefPubMedCentralGoogle Scholar
  104. 104.
    Rendi-Wagner P, Korinek M, Winkler B, Kundi M, Kollaritsch H, Wiedermann U. Persistence of seroprotection 10 years after primary hepatitis A vaccination in an unselected study population. Vaccine. 2007;25(5):927–31.PubMedCrossRefPubMedCentralGoogle Scholar
  105. 105.
    Schroter GP, West JC, Weil R 3rd. Acute bacteremia in asplenic renal transplant patients. JAMA. 1977;237(20):2207–8.PubMedCrossRefPubMedCentralGoogle Scholar
  106. 106.
    Mermel LA, Maki DG. Bacterial pneumonia in solid organ transplantation. Semin Respir Infect. 1990;5(1):10–29.PubMedPubMedCentralGoogle Scholar
  107. 107.
    Haemophilus influenzae invasive disease among children aged <5 years – California, 1990–1996. MMWR Morb Mortal Wkly Rep. 1998;47(35):737–40.Google Scholar
  108. 108.
    Progress toward elimination of Haemophilus influenzae type b disease among infants and children – United States, 1987–1995. MMWR Morb Mortal Wkly Rep. 1996;45(42):901–6.Google Scholar
  109. 109.
    Pediatric bacterial meningitis surveillance – African region, 2002–2008. MMWR Morb Mortal Wkly Rep. 2009;58(18):493–7.Google Scholar
  110. 110.
    Sever MS, Yildiz A, Eraksoy H, Badur S, Yuksel-Onel D, Gorcin B, et al. Immune response to Haemophilus influenzae type B vaccination in renal transplant recipients with well-functioning allografts. Nephron. 1999;81(1):55–9.PubMedCrossRefPubMedCentralGoogle Scholar
  111. 111.
    Furth SL, Neu AM, Sullivan EK, Gensler G, Tejani A, Fivush BA. Immunization practices in children with renal disease: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Nephrol. 1997;11(4):443–6.PubMedCrossRefPubMedCentralGoogle Scholar
  112. 112.
    Laube GF, Berger C, Goetschel P, Leumann E, Neuhaus TJ. Immunization in children with chronic renal failure. Pediatr Nephrol. 2002;17(8):638–42.PubMedCrossRefPubMedCentralGoogle Scholar
  113. 113.
    Gennery AR, Cant AJ, Spickett GP, Walshaw D, Hunter S, Hasan A, et al. Effect of immunosuppression after cardiac transplantation in early childhood on antibody response to polysaccharide antigen. Lancet. 1998;351(9118):1778–81.PubMedCrossRefPubMedCentralGoogle Scholar
  114. 114.
    Urschel S, Cremer S, Birnbaum J, Dallapozza R, Fuchs A, Jager G, et al. Lack of serologic immunity against vaccine-preventable diseases in children after thoracic transplantation. Transpl Int. 2010;23(6):619–27.PubMedCrossRefPubMedCentralGoogle Scholar
  115. 115.
    Balloni A, Assael BM, Ghio L, Pedrazzi C, Nebbia G, Gridelli B, et al. Immunity to poliomyelitis, diphtheria and tetanus in pediatric patients before and after renal or liver transplantation. Vaccine. 1999;17(20–21):2507–11.PubMedCrossRefPubMedCentralGoogle Scholar
  116. 116.
    Hospital-associated measles outbreak – Pennsylvania, March–April 2009. MMWR Morb Mortal Wkly Rep. 2012;61(2):30–2.Google Scholar
  117. 117.
    Chen TH, Kutty P, Lowe LE, Hunt EA, Blostein J, Espinoza R, et al. Measles outbreak associated with an international youth sporting event in the United States. Pediatr Infect Dis J. 2007;29(9):794–800.CrossRefGoogle Scholar
  118. 118.
    Greenland K, Whelan J, Fanoy E, Borgert M, Hulshof K, Yap KB, et al. Mumps outbreak among vaccinated university students associated with a large party, the Netherlands, 2010. Vaccine. 2012 Jun 29;30(31):4676–80.PubMedCrossRefPubMedCentralGoogle Scholar
  119. 119.
    Marin M, Quinlisk P, Shimabukuro T, Sawhney C, Brown C, Lebaron CW. Mumps vaccination coverage and vaccine effectiveness in a large outbreak among college students – Iowa, 2006. Vaccine. 2008;26(29–30):3601–7.PubMedCrossRefPubMedCentralGoogle Scholar
  120. 120.
    Zipprich J, Winter K, Hacker J, Xia D, Watt J, Harriman K, et al. Measles outbreak – California, December 2014–February 2015. MMWR Morb Mortal Wkly Rep. 2015;64(6):153–4.PubMedPubMedCentralGoogle Scholar
  121. 121.
    Flynn JT, Frisch K, Kershaw DB, Sedman AB, Bunchman TE. Response to early measles-mumps-rubella vaccination in infants with chronic renal failure and/or receiving peritoneal dialysis. Adv Perit Dial. 1999;15:269–72.PubMedPubMedCentralGoogle Scholar
  122. 122.
    Schulman SL, Deforest A, Kaiser BA, Polinsky MS, Baluarte HJ. Response to measles-mumps-rubella vaccine in children on dialysis. Pediatr Nephrol. 1992;6(2):187–9.PubMedCrossRefPubMedCentralGoogle Scholar
  123. 123.
    Mori K, Kawamura K, Honda M, Sasaki N. Responses in children to measles vaccination associated with perirenal transplantation. Pediatr Int. 2009;51(5):617–20.PubMedCrossRefPubMedCentralGoogle Scholar
  124. 124.
    Rand EB, McCarthy CA, Whitington PF. Measles vaccination after orthotopic liver transplantation. J Pediatr. 1993;123(1):87–9.PubMedCrossRefPubMedCentralGoogle Scholar
  125. 125.
    Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(RR-2):1–24.PubMedPubMedCentralGoogle Scholar
  126. 126.
    Meeuwis KA, Melchers WJ, Bouten H, van de Kerkhof PC, Hinten F, Quint WG, et al. Anogenital malignancies in women after renal transplantation over 40 years in a single center. Transplantation. 2012 May 15;93(9):914–22.PubMedCrossRefPubMedCentralGoogle Scholar
  127. 127.
    Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant. 2004;4(6):905–13.PubMedCrossRefPubMedCentralGoogle Scholar
  128. 128.
    Kellerman L, Neugut A, Burke B, Mancini D. Comparison of the incidence of de novo solid malignancies after heart transplantation to that in the general population. Am J Cardiol. 2009;103(4):562–6.PubMedCrossRefPubMedCentralGoogle Scholar
  129. 129.
    Malouf MA, Hopkins PM, Singleton L, Chhajed PN, Plit ML, Glanville AR. Sexual health issues after lung transplantation: importance of cervical screening. J Heart Lung Transplant. 2004;23(7):894–7.PubMedCrossRefPubMedCentralGoogle Scholar
  130. 130.
    Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002;347(21):1645–51.PubMedCrossRefPubMedCentralGoogle Scholar
  131. 131.
    Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol. 2006;107(1):18–27.PubMedCrossRefPubMedCentralGoogle Scholar
  132. 132.
    Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6(5):271–8.PubMedCrossRefPubMedCentralGoogle Scholar
  133. 133.
    Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006;95(11):1459–66.PubMedPubMedCentralCrossRefGoogle Scholar
  134. 134.
    Kumar D, Unger ER, Panicker G, Medvedev P, Wilson L, Humar A. Immunogenicity of quadrivalent human papillomavirus vaccine in organ transplant recipients. Am J Transplant. 2013;13(9):2411–7.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Pediatric Infectious Diseases, Immunocompromised Host Infectious DiseaseCincinnati Children’s Hospital Medical Center & University of CincinnatiCincinnatiUSA
  2. 2.Transplant and Immunocompromised Host Infectious Diseases, Division of Infectious Diseases, Massachusetts General HospitalTravelers’ Advice and Immunization Center, Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical SchoolBostonUSA

Personalised recommendations